TRuE-AD3 supplemental data and PLS

Published: 6 May 2025| Version 1 | DOI: 10.17632/t4npyttrbf.1
Contributor:
Howard Kallender

Description

These are supplemental data and a plain-language summary to the article titled "Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study", which was published in the Journal of the American Academy of Dermatology

Files

Categories

Ruxolitinib, Atopic Dermatitis, Eczema, Janus Kinase

Licence